Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Idera Pharma's IMO-2125 shows encouraging action in early-stage melanoma study; shares ahead 15% premarket

Published 09/11/2017, 07:55 AM
Updated 09/11/2017, 07:55 AM
© Reuters. Idera Pharma's IMO-2125 shows encouraging action in early-stage melanoma study; shares ahead 15% premarket
  • Idera Pharmaceuticals (NASDAQ:IDRA) is up 15% premarket on increased volume in response to its announcement of positive data in a Phase 1 clinical trial assessing IMO-2125, combined with Bristol-Myers Squibb's YERVOY (ipilimumab), in patients with treatment-resistant melanoma. The data were presented at ESMO in Madrid.
  • The dose selection process involved 18 patients, 17 of whom progressed after receiving Bristol-Myers' OPDIVO (nivolumab) or Merck (NYSE:MRK)'s KEYTRUDA (pembrolizumab). Six of nine patients who received the recommended Phase 2 dose of 8 mg of IMO-2125 experienced disease control, including one complete responder and three partial responders.
  • The IMO-2125/YERVOY combination was tolerable at all doses studied.
  • The target number of patients has been expanded in the ongoing Phase 2 expansion to include patients who have received prior treatment with YERVOY.
  • A Phase 3 study in PD-1-refractory melanoma will commence in Q1 2018.
  • IMO-2125 is an agonist of endosomal Toll-like receptor (TLR) 9, a cell surface protein that plays a key role in pathogen recognition and innate immunity.
  • The company will host a webcast this morning at 9:00 am ET to discuss the results.
  • Previously: Idera's IMO-2125 an Orphan Drug in U.S. for advanced melanoma; shares ahead 5% premarket (June 23)
  • Now read: Idera Pharmaceuticals (IDRA) Presents At Wedbush PacGrow Healthcare Conference - Slideshow

Original article

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.